High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Table 1 Clinical Characteristics of patients with BCMA-CD38 CAR-T at baseline

NO.	Age	Months of MM	Stage (ISS)	Subtype	EM	Cytogenetic abnormalities	Prior treatments				MRD (%)
NO.	Age	Months of MM	Stage (ISS)	Subtype	EM	Cytogenetic abnormalities	Prior lines	PI	IMID	ASCT	MRD (%)
1	62	6	III	κ	No	1q21 (9.0%)	2	BTZ		No	6.96
2	60	60	III	IgA-λ	No	1q21 (14.0%), RB1 (13.0%), D13S319 (13.0%)	3	BTZ	Thal, Lenal, Pomal	Yes	3.68
3	50	18	I	IgG-κ	No	1q21 (31%), Del17p (13%)	2	BTZ		Yes	8.80
4	78	72	III	IgA-λ	Yes	1q21 (26.0%), Del17p (20.0%)	3	BTZ	Thal, Lenal	No	13.50
5	70	66	I	κ	No	Del17p (24.0%)	3	BTZ	Lenal Thal	No	9.34
6	66	14	III	IgG-λ	Yes	1q21 (12%)	3	BTZ	Lenal	No	32.21
7	57	46	III	λ	No	No	3	BTZ,	Thal	No	4.26
8	57	33	III	λ	Yes	No	3	BTZ	Thal	No	3.22
9	64	43	III	IgG-κ	No	No	3	BTZ	Thal, Lenal	No	0.95
10	55	10	III	IgA-κ	No	No	2	BTZ		No	4.31
11	74	4	III	IgA-κ	Yes	No	2	BTZ		No	33.00
12	63	42	III	IgG-κ	Yes	1q21 (62.0%)	2	BTZ		No	5.46
13	57	5	III	IgA-λ	Yes	1q21 (24.0%)	2	BTZ	Thal	No	21.04
14	53	39	II	IgG-λ	Yes	1q21 (27.0%)	3	BTZ	Thal, Lenal Pomal	No	2.92
15	48	24	III	IgG-κ	Yes	1q21 (11.2%)	3	BTZ		Yes	5.03
16	55	7	IIII	IgA-κ	No	1q21 (45.0%)	3	BTZ		No	6.04

ISS International stage system, EM Extramedullary lesions, PI Proteasome inhibitor, IMID immunomodulatory agents, ASCT Autologous hematopoietic stem cell transplantation, BTZ Bortezomib, THAL Thalidomide, Lenal Lenalidomide, Pomal Pomalidomide, MRD Minimal residual disease

ISSN: 1756-9966